Craig & Toni Hofhine really do have their fingers on the "pulse"...

Craig & Toni Hofhine really do have their fingers on the "pulse" regarding Atcor.

Like Invaryant, I found the announcement of the partnership with Power a little out of left field.
It would seem Toni has developed a strategic plan to carve out a very strong positioning in the clinical trial business where we are able to offer prospective customers a strong "package" deal meeting all their needs.

A snippet from the press release - it is all about clinical trial diversity:



Biden announced changes back in December last year, but articles like the one below demonstrate the requirement is moving to top of mind for pharmaceutical companies running Phase 3 trials.



The US Food and Drug Administration (FDA) will soon require researchers and companies seeking approval for late-stage clinical trials to submit a plan for ensuring diversity among trial participants.The fraught quest to account for sex in biology researchMany scientists have applauded the move, which was laid out in a spending bill signed into law by US President Joe Biden in December 2022. They say that broadening participant pools is important to make medicines more effective across the whole population. But they are not yet convinced that the FDA will adequately enforce the new requirement.Nonetheless, “this is the biggest change in the regulatory landscape for clinical-trial diversity in the last three decades”, says Thomas Hwang, a physician at the Dana-Farber Cancer Institute in Boston, Massachusetts, who has expertise in pharmaceutical regulation1.

Well done team CardieX